Gemcitabine: cutaneous, hepatic and vascular disorders.
In addition to the adverse effects shared by all cytotoxic drugs, gemcitabine carries a risk of Lyell syndrome and other related cutaneous disorders, various types of liver damage (sometimes with positive rechallenge), and arterial thrombosis sometimes associated with necrosis.
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D002481:Cellulitis / Q000139:chemically induced*; D056486:Chemical and Drug Induced Liver Injury; D003603:Cytotoxins / Q000009:adverse effects*; D003841:Deoxycytidine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D017277:Drug Approval; D005602:France; D006801:Humans; D007511:Ischemia / Q000139:chemically induced*; D009336:Necrosis / Q000139:chemically induced*; D012871:Skin Diseases / Q000139:chemically induced*; D013262:Stevens-Johnson Syndrome / Q000209:etiology*; D014652:Vascular Diseases / Q000139:chemically induced*; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003603:Cytotoxins; D003841:Deoxycytidine; D000093542:Gemcitabine